0000000000202129

AUTHOR

Arrigo F G Cicero

showing 27 related works from this author

Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials.

2019

International audience; Recently, concerns regarding the safety of red yeast rice (RYR) have been raised after the publication of some case reports claiming toxicity. Since the previous meta-analyses on the effects of RYR were mainly focused on its efficacy to improve lipid profile and other cardiovascular parameters, we carried out a meta-analysis on safety data derived from the available randomized controlled clinical trials (RCTs). Primary outcomes were musculoskeletal disorders (MuD). Secondary outcomes were non-musculoskeletal adverse events (Non-MuD) and serious adverse events (SAE). Subgroups analyses were carried out considering the intervention (RYR alone or in association with oth…

0301 basic medicinemedicine.medical_specialty[SDV]Life Sciences [q-bio]PlaceboMusculoskeletal disorderslaw.invention03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRandomized controlled triallawInternal medicineNon-musculoskeletal adverse eventmedicineRed yeast riceHumansMusculoskeletal DiseasesAdverse effectRandomized Controlled Trials as TopicPharmacologyBiological Productsbusiness.industryMusculoskeletal disorderOdds ratioNon-musculoskeletal adverse eventsSerious adverse events[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good health[SDV] Life Sciences [q-bio]Clinical trial030104 developmental biologyRed yeast riceTolerability030220 oncology & carcinogenesisMeta-analysisDietary SupplementsSafetybusinessPharmacological research
researchProduct

Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease R…

2017

Introduction: There is a growing interest in nutraceuticals improving cardiovascular risk factor levels and related organ damage. Methods: This double-blind, placebo-controlled randomized clinical trial aims to compare the effect of a combined nutraceutical containing red yeast rice (10 mg), phytosterols (800 mg), and l-tyrosol (5 mg) on lipid profile, blood pressure, endothelial function, and arterial stiffness in a group of 60 patients with polygenic hypercholesterolemia resistant to Mediterranean diet. Results: After 8 weeks of treatment, when compared to the placebo group, the active treated patients experienced a more favorable percentage change in total cholesterol (−16.3% vs 9.9…

MaleBlood Pressure030204 cardiovascular system & hematologyGastroenterologychemistry.chemical_compoundDietary supplement0302 clinical medicineRisk FactorsPhytosterolPharmacology (medical)030212 general & internal medicineEndothelial dysfunctionOriginal ResearchFramingham Risk Scoremedicine.diagnostic_testAnticholesteremic AgentsFatty liverPhytosterolsGeneral MedicineMiddle AgedDietary supplementsCholesterolBiochemistryCardiovascular DiseasesFemaleNutraceuticalsNutraceuticalAdultmedicine.medical_specialtyl-TyrosolHypercholesterolemiaPlacebo03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansRisk factorBiological ProductsCholesterolbusiness.industryHemodynamicsmedicine.diseaseCardiovascular disease riskBlood pressurechemistryRed yeast riceArterial stiffnessLipid profilebusinessBiomarkers
researchProduct

Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper

2018

Current evidence shows that cholesterol management either reduces the likelihood of cardiovascular disease (CVD) or slows down its progression. Hence, it is important that all health professionals make appropriate use of all the available intervention strategies to control risk factors: from dietary improvement and positive lifestyle changes to the use of functional foods, food supplements, and drugs. This review examines the effect of the most frequently occurring cholesterol-lowering substances in functional foods or in supplements across Europe, namely plant sterols and stanols, monacolin K found in red yeast rice, berberine and beta-glucans. We conclude that currently available suppleme…

ConsensusFunctional foodsClinical Decision-MakingFood supplementDisease030204 cardiovascular system & hematologyLDL03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalPlasma cholesterolRisk FactorsEnvironmental healthFood supplementsRed yeast riceMedicineAnimalsHumans030212 general & internal medicineCardiovascular risk; Cholesterol; Food supplements; Functional foods; LDL cholesterol; Primary prevention; Animals; Biomarkers; Cardiovascular Diseases; Cholesterol LDL; Clinical Decision-Making; Consensus; Dyslipidemias; Evidence-Based Medicine; Humans; Protective Factors; Risk Factors; Diet Healthy; Dietary Supplements; Functional Food; Risk Reduction BehaviorDyslipidemiasPharmacologyLdl cholesterolHealthyEvidence-Based MedicinePrimary preventionCholesterolbusiness.industryFunctional foodFood supplementation functional foods cholesterol LDL-cholesterol cardiovascular risk primary preventionCholesterol LDLProtective FactorsCardiovascular riskDietCardiovascular risk; Cholesterol; Food supplements; Functional foods; LDL cholesterol; Primary prevention; PharmacologyYoung ageCholesterolchemistryCardiovascular DiseasesDietary SupplementsLDL cholesterolPosition paperDiet HealthybusinessRisk Reduction BehaviorBiomarkers
researchProduct

Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features

2020

Abstract Background and aims Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by extremely elevated plasma levels of low density lipoprotein cholesterol (LDL-C) and high risk of premature atherosclerotic cardiovascular disease (ASCVD). HoFH is caused by pathogenic variants in several genes, such as LDLR, APOB and PCSK9, responsible for autosomal dominant hypercholesterolemia (ADH), and LDLRAP1 responsible for autosomal recessive hypercholesterolemia (ARH). Aim of this study was the review of the clinical and molecular features of patients with HoFH identified in Italy from 1989 to 2019. Methods Data were collected from lipid clinics and laboratories, …

Adult0301 basic medicinemedicine.medical_specialtyCandidate geneCandidate geneGenotype-phenotype correlationApolipoprotein BCandidate genes; Genotype-phenotype correlations; Homozygous familial hypercholesterolemia; Pathogenic variantsHomozygous familial hypercholesterolemiaGenotype-phenotype correlationsFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosityCandidate genesHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansbiologybusiness.industryPCSK9HomozygoteGenetic disorderPathogenic variantsCandidate genes; Genotype-phenotype correlations; Homozygous familial hypercholesterolemia; Pathogenic variants;medicine.diseasePhenotype030104 developmental biologyEndocrinologyItalyReceptors LDLAutosomal Recessive HypercholesterolemiaMutationLDL receptorbiology.proteinlipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular Medicinebusiness
researchProduct

Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia

2022

Introduction: Inclisiran is a novel posttranscriptional gene silencing therapy that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis by RNA interference and has a potent, dose-dependent, durable effect in lowering LDL-C, and therefore is an effective drug to treat dyslipidemia, reducing the risk for acute cardiovascular (CV) events. It is safe and well-tolerated. Areas covered: This paper aims to review the mechanism of action of inclisiran while evaluating its efficacy and safety in the treatment of dyslipidemia from data of the clinical trials in the ORION program. Expert opinion: Data from the clinical trials in the ORION program demonstrated efficacy and safety o…

DrugSmall interfering RNAmedia_common.quotation_subjectHypercholesterolemiaPlaceboBioinformaticsLDLPCSK9RNA interferencemedicineAnimalsHumansPharmacology (medical)Gene SilencingRNA Small InterferingAdverse effectDyslipidemiasmedia_commontherapy.business.industryPCSK9General Medicinemedicine.diseaseClinical trialCardiovascular DiseasesAtherosclerosis inclisiran LDL PCSK9 RNA therapy Animals Cardiovascular Diseases Dyslipidemias Gene Silencing Humans Hypercholesterolemia Proprotein Convertase 9 RNA Small InterferingAtherosclerosiRNAProprotein Convertase 9businessinclisiranDyslipidemiaExpert Opinion on Drug Safety
researchProduct

Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study

2021

The Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension conceived and designed an ad hoc study aimed at searching for prognostic cut-off values of serum uric acid (SUA) in predicting combined (fatal and non-fatal) cerebrovascular (CBV) events in the whole database. The URic acid Right for heArt Health study is a nationwide, multicenter, observational cohort study involving data on subjects aged 18-95 years recruited on a regional community basis from all the territory of Italy under the patronage of the Italian Society of Hypertension with a mean follow-up period of 120.7 ± 61.8 months. A total of 14,588 subjects were included in the analysis. A prognos…

medicine.medical_specialtySettore MED/09 - Medicina Internauric acid cardiovascular riskserum uric acid; stroke; hypertension; cardiovascular prevention; cardiovascular diseasechemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansStrokeuric acid hypertensionbusiness.industryConfoundingPrognosismedicine.diseaseConfidence intervalUric AcidStrokechemistryHypertensionUric acidbusinessBody mass indexCohort studyKidney disease
researchProduct

Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials.

2019

The aim of this study is to assess the impact of a combination of berberine and silymarin on serum lipids and fasting plasma glucose (FPG) through a systematic review of literature and meta-analysis of the available randomized, double-blind, placebo-controlled clinical trials (RCTs). A systematic literature search in SCOPUS, PubMed-Medline, ISI Web of Science, and Google Scholar databases was conducted up to October 2, 2018, in order to identify RCTs assessing changes in plasma concentrations of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and FPG during treatment with berberine and silymarin in combina…

Blood Glucosemedicine.medical_specialtysilymarinReviewsBlood lipidsberberine; cholesterol; fasting plasma glucose; meta-analysis; nutraceutical; silymarin; Berberine; Blood Glucose; Double-Blind Method; Fasting; Humans; Lipids; Randomized Controlled Trials as Topic; SilymarinReviewPlaceboGastroenterologymeta-analysiDouble blind03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBerberineDouble-Blind MethodInternal medicineberberineMedicineHumansfasting plasma glucoseRandomized Controlled Trials as TopicPharmacology0303 health sciencesbusiness.industryCholesterolData synthesis030302 biochemistry & molecular biologycholesterolFastingLipidsClinical trialmeta-analysischemistrymeta‐analysis030220 oncology & carcinogenesisMetabolic effectsMeta-analysisnutraceuticalCardiology and Cardiovascular Medicinebusiness
researchProduct

Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies

2020

Alpha-lipoic acid (ALA) is a natural short-chain fatty acid that has attracted great attention in recent years as an antioxidant molecule. However, some concerns have been recently raised regarding its safety profile. To address the issue, we aimed to assess ALA safety profile through a systematic review of the literature and a meta-analysis of the available randomized placebo-controlled clinical studies. The literature search included EMBASE, PubMed Medline, SCOPUS, Google Scholar, and ISI Web of Science by Clarivate databases up to 15th August 2020. Data were pooled from 71 clinical studies, comprising 155 treatment arms, which included 4749 subjects with 2558 subjects treated with ALA an…

:Chemicals and Drugs::Pharmaceutical Preparations::Placebos [Medical Subject Headings]Physiologyα -lipoic acid ; thioctic acid ; dietary supplement ; safety ; meta-analysisClinical BiochemistryDisease030204 cardiovascular system & hematologyBiochemistrymeta-analysi:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antioxidants [Medical Subject Headings]Dietary supplementchemistry.chemical_compound0302 clinical medicinethioctic aciddietary supplement meta-analysis safety thioctic acid α-lipoic acid:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic [Medical Subject Headings]α-lipoic acidLipoic acidSafety profile:Publication Type::Study Characteristics::Meta-Analysis [Medical Subject Headings]Suplementos dietéticosMeta-analysis:Technology and Food and Beverages::Food and Beverages::Food::Dietary Supplements [Medical Subject Headings]SafetysafetyAlpha-lipoic acidmedicine.medical_specialtyMEDLINEÁcido tióctico030209 endocrinology & metabolismPlacebo:Chemicals and Drugs::Organic Chemicals::Sulfur Compounds::Thiophenes::Thioctic Acid [Medical Subject Headings]Article:Health Care::Environment and Public Health::Public Health::Accidents::Accident Prevention::Safety [Medical Subject Headings]03 medical and health sciencesα‐lipoic acidThioctic acidInternal medicineDiabetes mellitusmedicineMetaanálisisAdverse effectSeguridad:Diseases::Cardiovascular Diseases [Medical Subject Headings]Molecular Biology:Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids Volatile [Medical Subject Headings]business.industryRevisión sistemáticalcsh:RM1-950Cell Biologymedicine.disease:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Food Habits::Smoking [Medical Subject Headings]meta-analysisMeta-analysislcsh:Therapeutics. Pharmacologychemistry:Diseases::Nervous System Diseases [Medical Subject Headings]dietary supplementMeta‐analysisbusinessAntioxidants
researchProduct

Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years

2020

Serum uric acid (SUA) levels discriminating across the different strata of cardiovascular risk is still unknown. By utilizing a large population-based database, we assessed the threshold of SUA that increases the risk of total mortality and cardiovascular mortality (CVM). The URRAH study (Uric Acid Right for Heart Health) is a multicentre retrospective, observational study, which collected data from several large population-based longitudinal studies in Italy and subjects recruited in the hypertension clinics of the Italian Society of Hypertension. Total mortality was defined as mortality for any cause, CVM as death due to fatal myocardial infarction, stroke, sudden cardiac death, or heart…

Malemedicine.medical_specialtySettore MED/09 - Medicina Internaepidemiology; heart failure; humans; risk; uric acid; Cause of Death; Female; Humans; Italy; Male; Middle Aged; Mortality; Practice Patterns Physicians'; Quality Improvement; Risk Assessment; Risk Factors; Uric Acid; Cardiovascular Diseases; Hypertension; Hyperuricemiaheart failurePractice PatternsHyperuricemia030204 cardiovascular system & hematologyepidemiology; heart failure; humans; risk; uric acidRisk AssessmentSudden cardiac death03 medical and health sciences0302 clinical medicineuric acidRisk FactorsInternal medicineCause of DeathEpidemiologyInternal MedicineMedicine030212 general & internal medicineHyperuricemiaMyocardial infarctionhumanMortalityPractice Patterns Physicians'humansStrokeriskEpidemiology heart failure humans risk uric acid.Physicians'business.industryProportional hazards modelHazard ratioUric acid cardiovascular mortality epidemiologyMiddle Agedmedicine.diseaseQuality ImprovementItalyCardiovascular DiseasesHeart failureHypertensionFemaleepidemiologybusiness
researchProduct

Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfu…

2015

Objective Conflicting evidence exists on the benefits of treating patients with coronary artery disease and preserved left ventricular ejection fraction (LVEF) with an ACE inhibitor. This retrospective analysis of the SMILE-4 Study sought to compare the efficacy of zofenopril 60 mg plus acetylsalicylic acid (ASA) versus ramipril 10 mg plus ASA 100 mg in patients with acute myocardial infarction (AMI) and heart failure, according to an impaired or preserved LVEF. Methods The primary study end point was 1-year combined occurrence of death or hospitalisation for cardiovascular causes. A preserved LVEF was defined by a baseline LVEF >40% and an impaired one by an LVEF ≤40%. Results 448 patients…

Ramiprilmedicine.medical_specialtyacute myocardial infarctionInfarctionramiprilCoronary Artery DiseaseCoronary artery diseasechemistry.chemical_compoundInternal medicinemedicinezofenopril1506cardiovascular diseasesMyocardial infarctionleft ventricular dysfunctionEjection fractionbusiness.industryleft ventricular ejection fractionmedicine.diseaseZofenoprilangiotensin-converting enzyme inhibitorsangiotensin-converting enzyme inhibitorchemistryacute myocardial infarction; angiotensin-converting enzyme inhibitors; left ventricular dysfunction; left ventricular ejection fractionHeart failureACE inhibitorcardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologyBiomedical engineeringmedicine.drugOpen Heart
researchProduct

Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directo…

2020

Cardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin-Angiotensin System inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental models. Evidence in humans is lacking that those mechanisms are actually occurring in the present…

0301 basic medicineAngiotensin-Converting Enzyme InhibitorsDiseaseoutcomescardiovascular diseases; COVID-19; hypertension; infection; outcomes; Betacoronavirus; COVID-19; Cardiovascular Diseases; Humans; Hypertension; Italy; SARS-CoV-2; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Coronavirus Infections; Pandemics; Pneumonia Viral; Renin-Angiotensin SystemRenin-Angiotensin System0302 clinical medicinecardiovascular diseaseViralAngiotensin Receptor AntagonistsbiologyAngiotensin Receptor AntagonistAntihypertensive AgentItalyoutcomeAngiotensin Receptor BlockersCoronavirus InfectionsCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyhypertensionCoronavirus disease 2019 (COVID-19)Pneumonia ViralBetacoronavirusAngiotensin Receptor Antagonists03 medical and health sciencesPharmacotherapyRenin–angiotensin systemInternal MedicinemedicineHumansIntensive care medicinePandemicsAntihypertensive Agentsoutcomes.BetacoronaviruPandemicCoronavirus InfectionSARS-CoV-2business.industryOutbreakCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin-converting enzymePneumoniacardiovascular diseases; COVID-19; hypertension; infection; outcomesinfectioncardiovascular diseases030104 developmental biologybiology.proteincardiovascular diseases; COVID-19; hypertension; infection; outcomes; betacoronavirus; cardiovascular diseases; humans; hypertension; Italy; angiotensin receptor antagonists; angiotensin-converting enzyme inhibitors; antihypertensive agents; coronavirus infections; pandemics; pneumonia viral; renin-angiotensin systembusiness030217 neurology & neurosurgery
researchProduct

Natural approaches in metabolic syndrome management

2017

Metabolic syndrome (MetS) is characterized as a group of cardiometabolic risk factors that raise the risk for heart disease and other health problems, such as diabetes mellitus and stroke. Treatment strategies include pharmacologic interventions and supplementary (or "alternative") treatments. Nutraceuticals are derived from food sources (isolated nutrients, dietary supplements and herbal products) that are purported to provide health benefits, in addition to providing basic nutritional value. Nutraceuticals are claimed to prevent chronic diseases, improve health, delay the aging process, increase life expectancy, and support the structure and function of the body. The study of the benefici…

Polyphenolmedicine.medical_specialtyHeart diseaseOmega-3 fatty acid030204 cardiovascular system & hematologyVitamin03 medical and health sciences0302 clinical medicineNutraceuticalmetabolicDiabetes mellitusMacroelementmedicineIn patient030212 general & internal medicineDosingIntensive care medicineStrokepolyphenolsmetabolic syndrome managementnutraceuticalsomega-3 fatty acidsbusiness.industryMedicine (all)General MedicinevitaminsCardiovascular risksyndromemedicine.diseaseMetabolic syndromeBiotechnologymacroelementsLife expectancyNutraceuticalMetabolic syndromebusinessState of the Art PapermanagementArchives of Medical Science
researchProduct

Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study

2015

Abstract The main guidelines for cardiovascular disease prevention suggest that nutraceuticals could be an efficacious tool to improve lipid pattern. Our aim was to carry out a clinical trial comparing the metabolic effects of a combined nutraceutical containing both red yeast rice and polyunsaturated fatty acids (PUFAs) and a phytosterol-based approach in a setting of clinical practice. This was a multicenter open study with parallel control. We consecutively enrolled 107 pharmacologically untreated subjects affected by primary polygenic hypercholesterolemia and metabolic syndrome, assigned to 8-week treatment with a combined treatment with red yeast rice (Dif1Stat®, including 5 mg monacol…

MaleSettore MED/09 - Medicina InternaMedicine (miscellaneous)PharmacologyTriglycerideDietary supplements; Hypercholesterolemia; Monacolins; Nutraceuticals; Phytosterols; PUFA; Red yeast rice; Medicine (miscellaneous); Nutrition and DieteticsDietary supplementchemistry.chemical_compoundPhytosterolAnticholesteremic AgentMetabolic Syndromechemistry.chemical_classificationMonacolinNutrition and DieteticsAnticholesteremic AgentsPhytosterolPhytosterolsDietary supplements; Hypercholesterolemia; Monacolins; Nutraceuticals; Phytosterols; PUFA; Red yeast rice; Adult; Anticholesteremic Agents; Biological Products; Cholesterol; Cholesterol LDL; Fatty Acids Unsaturated; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Metabolic Syndrome; Middle Aged; Phytosterols; Treatment Outcome; Triglycerides; Dietary Supplements; Medicine (miscellaneous); Nutrition and DieteticsLipidMiddle AgedDietary supplementsLipidsCholesterolTreatment OutcomeBiochemistryFatty Acids UnsaturatedBiological ProductFemalelipids (amino acids peptides and proteins)NutraceuticalNutraceuticalsLovastatinFull CommunicationsHumanmedicine.drugPolyunsaturated fatty acidAdultHypercholesterolemiaBiologyNutraceuticalMonacolinsmedicineRed yeast riceHumansLovastatinTriglyceridesBiological ProductsCholesterolCholesterol LDLmedicine.diseaseClinical trialRed yeast ricechemistryMetabolic syndromePUFAJournal of Medicinal Food
researchProduct

Future Perspectives in Nutraceutical Research

2021

Nutraceuticals are largely used by general population. During the last decades, academicians and industries are intensifying the research of new bioactive compounds in order to improve the quality of life and to prevent disease in humans. The quality of the published research is however not always based on the rules of the Good Clinical Practice nor finalized to create a new Evidence-Based nutraceutical sciences. This chapter will resume some basic rules that we will expect to be applied to nutraceutical research in the next years.

Clinical Practiceeducation.field_of_studyNutraceuticalmedia_common.quotation_subjectPopulationEngineering ethicsQuality (business)Businesseducationmedia_common
researchProduct

Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6…

2019

The objective was to evaluate the effects of 6 months of supplementation with Altilix&reg

0301 basic medicineSettore MED/09 - Medicina Internacynaragenetic structuresPlacebo-controlled study030204 cardiovascular system & hematologySettore BIO/09 - FisiologiaGastroenterology0302 clinical medicineDiabetes mellitusimmune system diseasescardiovascular diseasehemic and lymphatic diseasesBrachial arteryLuteolinNutrition and Dieteticsdiabetes mellituFatty liverhemic and immune systemsDietary supplementsMetabolic syndromeCardiovascular diseasesLivertype 2diabetes mellitusChlorogenic Acidlcsh:Nutrition. Foods and food supplymedicine.medical_specialtyWaistlcsh:TX341-641chemical and pharmacologic phenomenaCynaraPlacebometabolic syndromedietary supplements03 medical and health sciencesDouble-Blind MethodInternal medicineDiabetes mellitusmedicine.arterymedicinebusiness.industrynon-alcoholic fatty liver diseasemedicine.diseasecardiovascular diseases030104 developmental biologydietary supplementSteatosisMetabolic syndromebusinessFood ScienceNon-alcoholic fatty liver disease
researchProduct

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

2017

1.1. Cardiovascular disease and dyslipidemia: prevalence and global economic impact Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, reaching 31% of deaths in 2012 [1]. In particular, atherosclerosis and ischemic heart disease (IHD) are the main causes of premature death in Europe and are responsible for 42% of deaths in women and 38% in men under 75 years old [2]. The global economic impact of CVD is estimated to have been US $906 billion in 2015 and is expected to rise by 22% by 2030 [3]. Cardiovascular diseases also represent the major cause of disability in developed countries. It has been estimated that their growing burden could lead to a global increase in…

0301 basic medicineRED YEAST RICEDiseasePharmacologyPLACEBO-CONTROLLED TRIALchemistry.chemical_compound0302 clinical medicineCARDIOVASCULAR RISK-FACTORSFamily historyhealth care economics and organizationseducation.field_of_studyCONJUGATED LINOLEIC-ACIDOrvostudományokGeneral MedicinehumanitiesC-REACTIVE PROTEIN3. Good healthDENSITY-LIPOPROTEIN CHOLESTEROL030220 oncology & carcinogenesislipids (amino acids peptides and proteins)nutraceuticalLife Sciences & Biomedicineposition paperMODERATELY HYPERCHOLESTEROLEMIC SUBJECTSmedicine.medical_specialtyRANDOMIZED CONTROLLED-TRIALSeducationPopulationGuidelines/RecommendationsKlinikai orvostudományok03 medical and health sciencesMedicine General & InternallipidGeneral & Internal MedicineInternal medicineDiabetes mellitusmedicineCORONARY-HEART-DISEASERisk factoreducationFATTY LIVER-DISEASEScience & TechnologyCholesterolbusiness.industrydyslipidemia1103 Clinical Sciencesmedicine.disease030104 developmental biologychemistryrecommendationsEtiologybusinessDyslipidemiaArchives of medical science : AMS
researchProduct

May Measurement Month 2018: an analysis of blood pressure screening results from Italy

2020

Abstract Cardiovascular (CV) diseases are burdened by high mortality and morbidity, being responsible for half of the deaths in Europe. Although hypertension is recognized as the most important CV risk factor, hypertension awareness and blood pressure (BP) control are still unsatisfactory. In 2017, 30.6% of a >10 000 individual sample who took part in the May Measurement Month (MMM) campaign in Italy was found to have high BP. To raise awareness on the hypertension issue and to report BP data on a nation-wide scale in Italy. In the frame of the MMM campaign, an opportunistic cross-sectional survey of volunteers aged ≥18 was carried out in May 2018. Blood pressure measurement, the def…

Mean arterial pressure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineDiabetes mellitusHealth careControlmedicineAcademicSubjects/MED00200030212 general & internal medicineRisk factor1102 Cardiorespiratory Medicine and HaematologyNational healthbusiness.industryHigh mortalityBlood pressure Control Hypertension Screening TreatmentArticlesmedicine.diseasehypertension; blood pressure; screening; treatment; controlTreatmentBlood pressureCardiovascular System & HematologyHypertensionBlood pressureScreeningCardiology and Cardiovascular MedicinebusinessBody mass indexBlood pressure; Control; Hypertension; Screening; TreatmentDemography
researchProduct

High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid.

2021

Abstract Aims  Whether the association between uric acid (UA) and cardiovascular disease is influenced by some facilitating factors is unclear. The aim of this study was to investigate whether the risk of cardiovascular mortality (CVM) associated with elevated UA was modulated by the level of resting heart rate (HR). Methods and results  Multivariable Cox analyses were made in 19 128 participants from the multicentre Uric acid Right for heArt Health study. During a median follow-up of 11.2 years, there were 1381 cases of CVM. In multivariable Cox models both UA and HR, either considered as continuous or categorical variables were independent predictors of CVM both improving risk discriminat…

medicine.medical_specialtySympathetic nervous systemLongitudinal studyEpidemiologyHeart rate030204 cardiovascular system & hematologyCardiovascular03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineHeart rateSympathetic activityMedicine030212 general & internal medicineRisk factorMortalityProportional hazards modelbusiness.industryHazard ratioConfidence intervalmedicine.anatomical_structurechemistryCardiologyUric acidCardiovascular; Heart rate; Longitudinal study; Mortality; Sympathetic activity; Uric acidLongitudinal studyCardiology and Cardiovascular MedicinebusinessUric acidEuropean journal of preventive cardiology
researchProduct

Drug Induced Liver Injury (DILI) due to variability in monacolin K content in Red Yeast Rice (RYR): An expert opinion

2020

Abstract Introduction Red yeast rice (RYR) is an effective cholesterol-lowering nutraceutical reversibly inhibiting 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase. As liver damage is a possible (albeit rare) side effect of HMG-CoA inhibitors, it make sense to focus on the tolerability of the liver to RYR extracts. The aim of this paper is to offer an expert opinion on the risk of liver damage by the use of RYR extract. Methods A review of the available literature has been carried out and critically reviewed by the authors. Results According to a large meta-analysis of 53 randomized clinical trials comprising 112 treatment arms, which included 8535 subjects with 4437 in the RYR arm and …

nutrivigilancesafetyDrugSide effectmedia_common.quotation_subjectliver injury; monacolin K; nutrivigilance; red yeast rice; safety; tolerabilityPharmacologymonacolin K03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalRed yeast rice Liver injury Monacolin K Safety Tolerability NutrivigilanceRed yeast riceMedicinered yeast rice030212 general & internal medicinetolerabilityLiver injury Monacolin K Nutrivigilance Red yeast rice Safety Tolerabilitymedia_commonLiver injurybusiness.industryRyanodine receptormusculoskeletal systemmedicine.disease030205 complementary & alternative medicineCitrininComplementary and alternative medicinechemistryTolerabilitycardiovascular systembusinesstissuesliver injury
researchProduct

Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia

2021

IntroductionIn the absence of a European standardized postmarketing food supplement surveillance system (nutrivigilance), some member states and companies have developed their own approaches to monitoring potential adverse reactions to secure a high level of product safety. This paper describes the use of a nutrivigilance system in monitoring the incidence of spontaneously reported suspected adverse reactions associated with food supplements containing red yeast rice (RYR).Material and methodsWe report the data from a widely used product marketed under the trademark Armolipid/Armolipid Plus. Postmarketing information was collected in a voluntary nutrivigilance system established by the manu…

Adverse eventnutrivigilancedyslipidaemiaAdverse event Dyslipidaemia Nutrivigilance Red yeast rice SupplementsupplementConsumer safetyRS03 medical and health sciences0302 clinical medicineNutraceuticalRA0421Clinical ResearchEnvironmental healthRed yeast riceMedicinered yeast rice030212 general & internal medicineAdverse effectNutritionbusiness.industryMember statesIncidence (epidemiology)General Medicinemedicine.diseaseSafety profilebusinessDyslipidemiaArchives of Medical Science
researchProduct

Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding…

2017

Background: Results of previous clinical trials evaluating the effect of pistachio supplementation on endothelial reactivity (ER) are controversial. Aims: We aimed to assess the impact of pistachio on ER through systematic review of literature and meta-analysis of available randomized, controlled-feeding clinical studies (RCTs). Methods: The literature search included SCOPUS, PubMed-Medline, ISI Web of Science and Google Scholar databases up to 1st August 2017 to identify RCTs investigating the impact of pistachio on ER. Two independent reviewers extracted data on study characteristics, methods and outcomes. Overall, the impact of pistachio on ER was reported in 4 trials. Results: The meta-…

Isi web of sciencemedicine.medical_specialtyBrachial Artery030309 nutrition & dieteticsMEDLINEIndustrial and Manufacturing Engineeringbrachial artery diameter03 medical and health sciences0404 agricultural biotechnologyInternal medicinemedicine.arteryflow mediated dilatationmedicineHumansBrachial arteryPistachioRandomized Controlled Trials as Topic0303 health sciencesbusiness.industry04 agricultural and veterinary sciencesGeneral Medicine040401 food scienceDietendothelial reactivityStudy CharacteristicsSurgeryVasodilationmeta-analysisClinical trialSystematic reviewMeta-analysisPistaciaEndothelium VascularbusinessPublication BiasBlood Flow VelocityFood ScienceCritical Reviews in Food Science and Nutrition
researchProduct

Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases

2018

Background: Polyphenols are bioactive compounds that can be found mostly in foods like fruits, cereals, vegetables, dry legumes, chocolate and beverages such as coffee, tea and wine. They are extensively used in the prevention and treatment of cardiovascular disease (CVD) providing protection against many chronic illnesses. Their effects on human health depend on the amount consumed and on their bioavailability. Many studies have demonstrated that polyphenols have also good effects on the vascular system by lowering blood pressure, improving endothelial function, increasing antioxidant defences, inhibiting platelet aggregation and low-density lipoprotein oxidation, and reducing inflammator…

0301 basic medicinePolyphenolcardiovascular risklignanAntioxidantmedicine.medical_treatmentInflammationPharmacologystilbenesmedicine.disease_cause03 medical and health sciencespreventionDiabetes mellitusDrug DiscoveryHumansMedicineAnimalsflavonoidLipoprotein oxidationEndothelial dysfunctionpolyphenolsPharmacologytherapytherapy.030109 nutrition & dieteticsphenolic acidbusiness.industrylignansfood and beveragesmedicine.diseasestilbeneCardiovascular DiseasesPolyphenolflavonoidspolyphenols; flavonoids; lignans; stilbenes; phenolic acids; prevention; therapy; cardiovascular riskmedicine.symptombusinessphenolic acidsOxidative stressLipoprotein
researchProduct

Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study

2020

Objective: To assess the prognostic cut-off values of serum uric acid (SUA) in predicting fatal and morbid heart failure in a large Italian cohort in the frame of the Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension. Methods: The URic acid Right for heArt Health (URRAH) study is a nationwide, multicentre, cohort study involving data on individuals aged 18-95 years, recruited on a community basis from all regions of Italy under the patronage of the Italian Society of Hypertension with a mean follow-up period of 128 ± 65 months. Incident heart failure was defined on the basis of International Classification of Diseases Tenth Revision codes and double-c…

medicine.medical_specialtySettore MED/09 - Medicina InternaPhysiologyEpidemiologyCut-off value030204 cardiovascular system & hematologyCohort Studies03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusInternal MedicineMedicineHumans030212 general & internal medicineMortalityRisk factorCut-off value heart failure mortality uric acidHeart Failurebusiness.industryProportional hazards modelHazard ratioConfoundingcut-off value; heart failure; mortality; uric acidmedicine.diseaseUric AcidItalyHeart failureCohortHypertensionCardiologyCardiology and Cardiovascular MedicinebusinessCohort study
researchProduct

Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Pa…

2020

Food supplementation with Opuntia ficus-indica (OFI) has been associated with a significant reduction in total cholesterol, body fat, hyperglycemia and blood pressure. Since OFI may also have antioxidant and anti-atherogenic properties, we hypothesized that its supplementation might reduce atherogenic lipoproteins, including small, dense low-density lipoproteins (sdLDL). Forty-nine patients (13 men and 36 women, mean age: 56 &plusmn

0301 basic medicinecardiovascular riskmedicine.medical_specialtyOpuntia ficus-indicaAntioxidantWaistEndocrinology Diabetes and Metabolismmedicine.medical_treatmentlcsh:QR1-502Aspartate transaminase030204 cardiovascular system & hematologyPolysaccharideBiochemistrylcsh:MicrobiologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineMolecular Biologychemistry.chemical_classificationnutraceuticalslow-density lipoprotein cholesterol030109 nutrition & dieteticsbiologybusiness.industrydyslipidemiamedicine.disease<i>Opuntia ficus-indica</i>EndocrinologyBlood pressurechemistryUreabiology.proteinMetabolic syndromebusinessDyslipidemia
researchProduct

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

2017

In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is…

PhytochemicalsMedicine (miscellaneous)030204 cardiovascular system & hematologyPharmacologyIntestinal absorption0302 clinical medicineRisk FactorsDrug Interactions030212 general & internal medicineRandomized Controlled Trials as TopicNutrition and DieteticsEvidence-Based MedicineOrvostudományok3. Good healthObservational Studies as TopicLiverCardiovascular DiseasesFatty Acids Unsaturatedlipids (amino acids peptides and proteins)nutraceuticalposition papermedicine.medical_specialtyStatinCombination therapymedicine.drug_classKlinikai orvostudományok03 medical and health sciencesMeta-Analysis as TopiclipidmedicineHumansIntensive care medicineLife StyleTriglyceridesDyslipidemiasbusiness.industryProbioticsdyslipidemiaCholesterol HDLEvidence-based medicineCholesterol LDLmedicine.diseaseResidual riskIntestinal AbsorptionrecommendationsDietary SupplementsPosition paperObservational Studies as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemia
researchProduct

Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory …

2020

Extra virgin olive oil (EVOO) intake is associated with reduced cardiovascular risk, and its phenolic compound oleocanthal (OC) has anti-oxidant and anti-inflammatory properties. The cardiometabolic effects of EVOO with a high OC concentration have not been fully elucidated. We administered EVOO with a high OC concentration daily to 23 subjects with the metabolic syndrome (MetS) and hepatic steatosis (15 men and 8 women, age: 60 &plusmn

Polyphenolmedicine.medical_specialtyWaistEndocrinology Diabetes and Metabolismlcsh:QR1-502030204 cardiovascular system & hematologyBiochemistryArticlemetabolic syndromeoleocanthallcsh:Microbiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineOleocanthalmedicineIngestion030212 general & internal medicineMolecular BiologyCytokinepolyphenolsbiologybusiness.industryFatty liverCytokines metabolic syndrome oleocanthal olive oil polyphenols.medicine.diseaseolive oilcytokinesEndocrinologychemistryAlanine transaminasebiology.proteinSteatosisMetabolic syndromebusinessBody mass indexMetabolites
researchProduct

The Role of Nutraceuticals in Statin Intolerant Patients.

2018

Abstract Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activ…

Statinmedicine.drug_classDiseasecardiovascular risk ; dyslipidemia ; nutraceuticals ; position paper ; statin intolerance030204 cardiovascular system & hematologyBioinformaticsKlinikai orvostudományok03 medical and health sciences0302 clinical medicineNutraceuticalEzetimibeStatin intoleranceRed yeast riceMedicineHumansPosition paper030212 general & internal medicineEndothelial dysfunctionDyslipidemiasbusiness.industryClinical Studies as TopicOrvostudományokmedicine.diseaseCardiovascular risk3. Good healthDyslipidemiaDietary SupplementsArterial stiffnesslipids (amino acids peptides and proteins)nutraceuticalHydroxymethylglutaryl-CoA Reductase InhibitorNutraceuticalsHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDyslipidemiaposition papermedicine.drugstatin intoleranceHuman
researchProduct